蕲蛇酶与依达拉奉联合应用治疗急性脑梗死

Combined intravenous acutase and edaravone for acute cerebral infarction

目的研究蕲蛇酶与自由基清除剂依达拉奉联合治疗急性脑梗死的疗效。方法初次急性脑梗死患者81例,随机分为单独使用蕲蛇酶治疗组41例和蕲蛇酶联合依达拉奉治疗组40例。对两组的疗效进行对照研究。结果联合治疗组的疗效优于单独使用蕲蛇酶组(P<0.05)。治疗后30d联合治疗组NIHSS评分较单独使用蕲蛇酶治疗组显著下降(P<0.05)。结论急性脑梗死治疗时蕲蛇酶与依达拉奉联合能够更有效地减少神经功能缺损程度。

Objective To investigate the efficacy of combined intravenous acutase and edaravone on the patients with acute cerebral infarction. Methods Eighty-one patients with first acute cerebral infarction were assigned to the group treated with acutase and another group treated with a combination of intravenous acutase and edaravone. Control test was performed. Results The efficacy of therapeutic alliance group was better than the acutase alone treated group（ P 〈 0. 05 ）. NIHSS score decreased significantly in the therapeutic alliance group compared with the acutase alone treated group after thirty days treatment （ P 〈 0.05 ）. Conclusion Combined intravenous acutase and edaravone can more effectually diminished the level of neurologic impairment after acute cerebral infarction.